Page 7 - Altavant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Altavant Sciences Provides Update on Clinical Plan for PAH Candidate, Rodatristat Ethyl, at Upcoming American Thoracic Society Annual Meeting News provided by Share this article Share this article CARY, N.C. and BASEL, Switzerland, May 10, 2021 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, will be providing an update on the clinical development of rodatristat ethyl, the company's lead candidate for the treatment of pulmonary arterial hypertension (PAH), at the annual meeting of the Ameri...

Cary, N.C. and Basel, Switzerland s Finds Nebulized ALTA-2530 Retains Potency and Reaches Target Lung Tissues, Supporting Continued Investigation for Treatment of BOS April 26, 2021 11:34 ET | Source: Sumitovant Biopharma Sumitovant Biopharma New York, New York, UNITED STATES Cary, N.C. and Basel, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) -- – Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, presented results of in vitro and in vivo studies for nebulized ...

Zach Rand Creates Benefit To Raise Awareness For Pulmonary Hypertension in Celebration of World PH Day The event will star Ali Ewoldt, Max von Essen, Kara Lindsay, and more!by BWW News Desk On Thursday, May 6th, 2021, at 8PM, the Rand Family and many popular and talented Broadway performers invite you to "plug in for PH" as they shine a light on Pulmonary Hypertension (PH) at the 6th annual "Breathless on Broadway" in celebration of WORLD PH DAY. Streaming virtually this year, the event includes some of Broadway's favorites, including Aaron Lazar (The Phantom of the Opera, The Last Ship, A ...

Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA (vibegron), in the Journal of Urology Urovant Sciences, a wholly owned subsidiary of Sumitovant, announced today that the Journal of Urology has published positive safety and efficacy data from the GEMTESA (vibegron) double-blind 40-week extension study with patient data over a total exposure of 52 weeks (NCT03583372) in the print version of the Journal of Urology. The peer-reviewed publication is currently available online and the print arti...

Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids •LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline •Achieved six of seven key secondary endpoints including reduction of pain •Bone mineral density maintained at levels comparable to placebo •Data were included in U.S. New Drug Application for relugolix combination tablet for ut...